MX2024009188A - Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. - Google Patents
Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.Info
- Publication number
- MX2024009188A MX2024009188A MX2024009188A MX2024009188A MX2024009188A MX 2024009188 A MX2024009188 A MX 2024009188A MX 2024009188 A MX2024009188 A MX 2024009188A MX 2024009188 A MX2024009188 A MX 2024009188A MX 2024009188 A MX2024009188 A MX 2024009188A
- Authority
- MX
- Mexico
- Prior art keywords
- extended release
- dosing regimens
- injectable formulations
- regimens associated
- release paliperidone
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 239000007972 injectable composition Substances 0.000 title 1
- 229960001057 paliperidone Drugs 0.000 title 1
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960000635 paliperidone palmitate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para tratar pacientes con formulaciones de palmitato de paliperidona inyectable de acción prolongada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119405P | 2020-11-30 | 2020-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009188A true MX2024009188A (es) | 2024-08-06 |
Family
ID=75888043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006366A MX2023006366A (es) | 2020-11-30 | 2021-05-07 | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| MX2024009188A MX2024009188A (es) | 2020-11-30 | 2023-05-30 | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006366A MX2023006366A (es) | 2020-11-30 | 2021-05-07 | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11304951B1 (es) |
| EP (2) | EP4025188B1 (es) |
| JP (1) | JP7792959B2 (es) |
| KR (2) | KR102794804B1 (es) |
| CN (1) | CN116583270A (es) |
| AU (2) | AU2021386450B2 (es) |
| CA (1) | CA3203566A1 (es) |
| DK (1) | DK4025188T3 (es) |
| ES (1) | ES2973583T3 (es) |
| FI (1) | FI4025188T3 (es) |
| HR (1) | HRP20240074T1 (es) |
| HU (1) | HUE065573T2 (es) |
| IL (1) | IL303253A (es) |
| LT (1) | LT4025188T (es) |
| MX (2) | MX2023006366A (es) |
| PL (1) | PL4025188T3 (es) |
| PT (1) | PT4025188T (es) |
| RS (1) | RS65178B1 (es) |
| SI (1) | SI4025188T1 (es) |
| SM (1) | SMT202400077T1 (es) |
| TW (2) | TWI877363B (es) |
| WO (1) | WO2022111859A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023551009A (ja) | 2020-11-30 | 2023-12-06 | ヤンセン ファーマシューティカ エヌ．ベー． | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
| IL303253A (en) * | 2020-11-30 | 2023-07-01 | Janssen Pharmaceutica Nv | Dosing regimens associated with delayed-release injectable formulations of paliperidone |
| AU2021388842A1 (en) | 2020-11-30 | 2023-07-13 | Janssen Pharmaceutica Nv | Methods for ensuring resuspension of paliperidone palmitate formulations |
| LT4025187T (lt) | 2020-11-30 | 2024-02-12 | Janssen Pharmaceutica Nv | Dozavimo režimai, susiję su prailginto atpalaidavimo injekcinėmis paliperidono vaisto formomis |
| JP2024532195A (ja) | 2021-08-20 | 2024-09-05 | ヤンセン ファーマシューティカ エヌ．ベー． | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| US20080214808A1 (en) | 2005-04-25 | 2008-09-04 | Thomas Frederik Ernestine Spittaels | Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester |
| AU2008340101C1 (en) * | 2007-12-19 | 2025-03-06 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| NZ599558A (en) | 2009-10-30 | 2014-09-26 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
| PL2529757T3 (pl) | 2011-05-31 | 2014-04-30 | Farm Rovi Lab Sa | Formulacja implantu zawierającego paliperydon |
| WO2016157061A1 (en) * | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| EA037185B1 (ru) * | 2015-04-07 | 2021-02-17 | Янссен Фармацевтика Н.В. | Способ лечения психоза, шизофрении или биполярного расстройства |
| RU2699333C2 (ru) | 2015-06-19 | 2019-09-04 | Янссен Фармацевтика Нв | Устройства и способы для введения и смешивания лекарственного средства, а также обучение правильной технике для этого |
| WO2019118722A1 (en) | 2017-12-14 | 2019-06-20 | SpecGx LLC | One step milling process for preparing micronized paliperidone esters |
| IL303253A (en) * | 2020-11-30 | 2023-07-01 | Janssen Pharmaceutica Nv | Dosing regimens associated with delayed-release injectable formulations of paliperidone |
-
2021
- 2021-05-07 IL IL303253A patent/IL303253A/en unknown
- 2021-05-07 ES ES21724652T patent/ES2973583T3/es active Active
- 2021-05-07 CA CA3203566A patent/CA3203566A1/en active Pending
- 2021-05-07 SI SI202130102T patent/SI4025188T1/sl unknown
- 2021-05-07 KR KR1020237021429A patent/KR102794804B1/ko active Active
- 2021-05-07 WO PCT/EP2021/062147 patent/WO2022111859A1/en not_active Ceased
- 2021-05-07 KR KR1020257011387A patent/KR20250053980A/ko active Pending
- 2021-05-07 RS RS20240116A patent/RS65178B1/sr unknown
- 2021-05-07 EP EP21724652.9A patent/EP4025188B1/en active Active
- 2021-05-07 PT PT217246529T patent/PT4025188T/pt unknown
- 2021-05-07 SM SM20240077T patent/SMT202400077T1/it unknown
- 2021-05-07 CN CN202180080433.0A patent/CN116583270A/zh active Pending
- 2021-05-07 AU AU2021386450A patent/AU2021386450B2/en active Active
- 2021-05-07 MX MX2023006366A patent/MX2023006366A/es unknown
- 2021-05-07 HR HRP20240074TT patent/HRP20240074T1/hr unknown
- 2021-05-07 FI FIEP21724652.9T patent/FI4025188T3/fi active
- 2021-05-07 PL PL21724652.9T patent/PL4025188T3/pl unknown
- 2021-05-07 JP JP2023532489A patent/JP7792959B2/ja active Active
- 2021-05-07 DK DK21724652.9T patent/DK4025188T3/da active
- 2021-05-07 LT LTEPPCT/EP2021/062147T patent/LT4025188T/lt unknown
- 2021-05-07 TW TW110116515A patent/TWI877363B/zh active
- 2021-05-07 US US17/314,330 patent/US11304951B1/en active Active
- 2021-05-07 EP EP23219765.7A patent/EP4356966A3/en active Pending
- 2021-05-07 HU HUE21724652A patent/HUE065573T2/hu unknown
- 2021-05-07 TW TW114105894A patent/TW202539685A/zh unknown
-
2022
- 2022-04-13 US US17/719,686 patent/US20220249495A1/en not_active Abandoned
-
2023
- 2023-05-30 MX MX2024009188A patent/MX2024009188A/es unknown
-
2024
- 2024-06-20 AU AU2024204213A patent/AU2024204213A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202400851B (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| MX2024009188A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| MX2023006368A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| CL2019001292A1 (es) | Nuevos derivados de quinolina. | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| CL2020000301A1 (es) | Nuevos derivados de quinolina. | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| CO6300949A2 (es) | Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada | |
| WO2019099639A8 (en) | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| MX378969B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| BR112017000470A2 (pt) | composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção | |
| CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| CL2019003078A1 (es) | Nuevos derivados de pirazol bicíclicos. | |
| MY194576A (en) | Methods for the treatment of recurrent glioblastoma (rgbm) | |
| EA201992612A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза | |
| CL2021000529A1 (es) | Administración prolongada de lasmiditan por la noche para la prevención de la migraña | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| IL282538A (en) | Methods for manufacturing therapeutic delivery platforms | |
| MX2019001860A (es) | Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. |